News FocusClinical Trials

Nail-Biting Time for Trials of COX-2 Drugs

See allHide authors and affiliations

Science  03 Dec 2004:
Vol. 306, Issue 5702, pp. 1673-1675
DOI: 10.1126/science.306.5702.1673

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Preliminary studies suggest that the COX-2 inhibitor Celebrex may stem cancer and Alzheimer's disease, but testing these possibilities has just gotten tougher.